Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells

Rami G Azrak; Cheryl L Frank; Ali Ghadersohi; Youcef M Rustum

doi:10.4161/cbt.7.12.6939

Back

Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells

Journal article

Open access

Peer reviewed

Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells

Rami G Azrak, Cheryl L Frank, Ali Ghadersohi and Youcef M Rustum

Cancer biology & therapy, Vol.7(12), pp.1901-1908

12/2008

DOI: 10.4161/cbt.7.12.6939

PMID: 18981709

Files and links (1)

url

https://doi.org/10.4161/cbt.7.12.6939View

Published (Version of record) Open Access

Abstract

This study evaluates methylseleninic acid (MSeA) improvement of paclitaxel efficacy against human ovarian cancer (skov3) with regard to survivin expression. MSeA and paclitaxel alone and in concurrent or sequential combination treatments were tested. Cell growth/death was evaluated using SRB, trypan blue, colony formation and ELISA assays. Cells were transfected with survivin shRNA and survivin's expression was measured using RT-PCR and Western blots. Drugs interaction was further evaluated using isobologram analyses. Different treatments with MSeA did not enhance paclitaxel's efficacy in the wild type skov3. Silencing survivin had no effect on MSeA or paclitaxel efficacy when used alone or in concurrent combination. After sequential combination treatment, synergy and significant induction of apoptosis were observed in cells transfected with survivin shRNA. However, antagonism and minimal induction of apoptosis were observed in empty or scramble survivin shRNA transfected cells. In conclusion, these data suggest that synergy between MSeA and paclitaxel in skov3 is associated with silencing survivin expression.

Cell Death - drug effects

Cell Division - drug effects

Drug Synergism

Female

Gene Expression Regulation, Neoplastic - drug effects

Gene Silencing

Humans

Inhibitor of Apoptosis Proteins

Microtubule-Associated Proteins - genetics

Organoselenium Compounds - therapeutic use

Ovarian Neoplasms - drug therapy

Ovarian Neoplasms - genetics

Ovarian Neoplasms - pathology

Paclitaxel - therapeutic use

Survivin

Details

Title: Subtitle: Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells
Creators: Rami G Azrak - Roswell Park Cancer Institute
Cheryl L Frank
Ali Ghadersohi
Youcef M Rustum
Resource Type: Journal article
Publication Details: Cancer biology & therapy, Vol.7(12), pp.1901-1908
DOI: 10.4161/cbt.7.12.6939
PMID: 18981709
ISSN: 1538-4047
eISSN: 1555-8576
Grant note: CA016056 / NCI NIH HHS
Language: English
Date published: 12/2008
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984359942102771

Metrics

15 Record Views

6 Times Cited - Web of Science